<![CDATA[ Ongoing Projects - Aromics]]> <![CDATA[ Ongoing Projects - Aromics]]> http://aromics.es/rss/en/projects/ongoing-projects <![CDATA[]]> European flagAROMICS has a clear international vision. From its inception, the company has participated in the establishment of a biotechnology strategy in Europe to improve commercial and production activities of small and medium size companies.

AROMICS has proven experience in R&D Projects under various funding programs: European (Horizon 2020), national (CDTI) and local (ACC1Ó-FEDER). The active participation of the company in European funded R&D projects as well as membership in different European platforms enables the company to:

  • Be at the forefront of European research.
  • Identify, improve and implant new technologies with potential applications in the health sector(industry and clinical practice).
  • Favor technology transfer.
  • Share the costs of innovation through partnerships with other biotechnology and pharmaceutical companies.
]]> <![CDATA[CLINBERMES]]> The aim of the project is to develop a novel treatment for Malignant Mesothelioma, a rare, aggresive and poorly responsive cancer directly related to asbestos exposure. General objective pursued by the project include to complete non-regulatory preclinical studies and conduct a clinical trial in patients.

(Co-financed by the Horizon 2020 Programme of the European Union)

(Co-financed by CDTI through the Horizon Europe EIC Accelerator Seal of Excellence SME Programme)

]]> <![CDATA[G4-CANCER]]> The aim of the project is to develop an innovative platform for screening anti-tumour drugs, based on the identification and characterisation of G-quadruplex (G4) structures in oncogenes. These structures, which are complex and highly regulatory in nature, play a key role in both tumour progression and mechanisms of resistance to conventional therapies, and are therefore therapeutic targets of great interest.

(Cofinanced by the program  NUCLIS D’INNOVACIÓ TECNOLÒGICA - Projectes de Recerca Industrial i Desenvolupament Experimental - ACCIO 2022)

 

]]> <![CDATA[RNA targeting]]> Technical assessment and strategic definition of a family of RNA‑targeting molecules. 

Support from ACCIÓ – Generalitat de Catalunya under the Cupons Propietat Industrial i Intel·lectual programme)

Cofinanciado por el programa NUCLIS INNOVACIO TECNOLOGICA

 

 

 

 

]]>